Immune Microenvironment in Breast Cancer Metastasis

Overview

Journal Adv Exp Med Biol

Date 2025 Jan 17

PMID 39821036

Authors

Bin-Zhi Qian

Ruo-Yu Ma

Affiliations

Soon will be listed here.

Abstract

Metastatic disease is the final stage of breast cancer that accounts for vast majority of patient death. Mounting data over recent years strongly support the critical roles of the immune microenvironment in determining breast cancer metastasis. The latest single-cell studies provide further molecular evidence illustrating the heterogeneity of this immune microenvironment. This chapter summarizes major discoveries on the role of various immune cells in metastasis progression and discusses future research opportunities. Studies investigating immune heterogeneity within primary breast cancer and across different metastasis target organs can potentially lead to more precise treatment strategies with improved efficacy.

References

Aklilu M, Stadler W, Markiewicz M, Vogelzang N, Mahowald M, Johnson M . Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004; 15(7):1109-14. DOI: 10.1093/annonc/mdh280. View

Ali H, Jackson H, Zanotelli V, Danenberg E, Fischer J, Bardwell H . Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat Cancer. 2022; 1(2):163-175. DOI: 10.1038/s43018-020-0026-6. View

Andersson A, Larsson L, Stenbeck L, Salmen F, Ehinger A, Wu S . Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. Nat Commun. 2021; 12(1):6012. PMC: 8516894. DOI: 10.1038/s41467-021-26271-2. View

Andzinski L, Kasnitz N, Stahnke S, Wu C, Gereke M, von Kockritz-Blickwede M . Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 2015; 138(8):1982-93. DOI: 10.1002/ijc.29945. View

Arias-Pulido H, Cimino-Mathews A, Chaher N, Qualls C, Joste N, Colpaert C . The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Res Treat. 2018; 171(2):273-282. PMC: 6173952. DOI: 10.1007/s10549-018-4834-7. View

Arwert E, Harney A, Entenberg D, Wang Y, Sahai E, Pollard J . A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation. Cell Rep. 2018; 23(5):1239-1248. PMC: 5946803. DOI: 10.1016/j.celrep.2018.04.007. View

Beerling E, Seinstra D, de Wit E, Kester L, van der Velden D, Maynard C . Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity. Cell Rep. 2016; 14(10):2281-8. PMC: 4802222. DOI: 10.1016/j.celrep.2016.02.034. View

Blazquez R, Wlochowitz D, Wolff A, Seitz S, Wachter A, Perera-Bel J . PI3K: A master regulator of brain metastasis-promoting macrophages/microglia. Glia. 2018; 66(11):2438-2455. DOI: 10.1002/glia.23485. View

Bowman R, Klemm F, Akkari L, Pyonteck S, Sevenich L, Quail D . Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Rep. 2016; 17(9):2445-2459. PMC: 5450644. DOI: 10.1016/j.celrep.2016.10.052. View

10.

Cai C, Zeng D, Gao Q, Ma L, Zeng B, Zhou Y . Decreased ferroportin in hepatocytes promotes macrophages polarize towards an M2-like phenotype and liver fibrosis. Sci Rep. 2021; 11(1):13386. PMC: 8239022. DOI: 10.1038/s41598-021-92839-z. View

11.

Carlsten M, Childs R . Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications. Front Immunol. 2015; 6:266. PMC: 4462109. DOI: 10.3389/fimmu.2015.00266. View

12.

Cassetta L, Fragkogianni S, Sims A, Swierczak A, Forrester L, Zhang H . Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell. 2019; 35(4):588-602.e10. PMC: 6472943. DOI: 10.1016/j.ccell.2019.02.009. View

13.

Chen J, Yao Y, Gong C, Yu F, Su S, Chen J . CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011; 19(4):541-55. PMC: 3107500. DOI: 10.1016/j.ccr.2011.02.006. View

14.

Choi Y, Dieter J, Rothaeusler K, Luo Z, Baumgarth N . B-1 cells in the bone marrow are a significant source of natural IgM. Eur J Immunol. 2011; 42(1):120-9. PMC: 3426357. DOI: 10.1002/eji.201141890. View

15.

Chu J, Deng Y, Benson D, He S, Hughes T, Zhang J . CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2013; 28(4):917-27. PMC: 3967004. DOI: 10.1038/leu.2013.279. View

16.

Clark A, Matic Vignjevic D . Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol. 2015; 36:13-22. DOI: 10.1016/j.ceb.2015.06.004. View

17.

Condeelis J, Singer R, Segall J . The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol. 2005; 21:695-718. DOI: 10.1146/annurev.cellbio.21.122303.120306. View

18.

Coronella-Wood J, Hersh E . Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother. 2003; 52(12):715-38. PMC: 11033039. DOI: 10.1007/s00262-003-0409-4. View

19.

Cox T, Rumney R, Schoof E, Perryman L, Hoye A, Agrawal A . The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015; 522(7554):106-110. PMC: 4961239. DOI: 10.1038/nature14492. View

20.

Cui C, Chakraborty K, Tang X, Zhou G, Schoenfelt K, Becker K . Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021; 184(12):3163-3177.e21. PMC: 10712736. DOI: 10.1016/j.cell.2021.04.016. View